Imugene Ltd has released a press release.
First Complete Response in Concurrent BTKi azer-cel Cohort
Earlier from Imugene
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL
- First Patient in BTKi Combination Cohort of azer-cel study
- Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
- Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)